Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

NCT02757950 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02757950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02757950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
July 14, 2016
Completion date
May 31, 2017
Enrollment
2,462 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria